Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Ajjai Shivaram Alva, MBBS
Advertisement
Articles by Ajjai Shivaram Alva, MBBS
Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.
Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.
Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Alva on the Toxicity Profiles of TKIs in RCCPublished: January 6th 2020 | Updated:
Dr. Alva on TKI Monotherapy and Combinations for RCCPublished: January 22nd 2020 | Updated:
Dr. Alva on Results of the CABOSUN Trial in RCCPublished: February 4th 2020 | Updated:
Dr. Alva on the Shift Toward Combination Therapy in mRCCPublished: February 15th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5